Cooperative Agreement UG3CA311401
Award Date 7/1/26
Completion Date 6/30/29
Dollars Obligated $331K
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded the Regents of the University of Michigan a $2.86 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop and validate a novel microbial-based therapeutic strategy targeting colibactin, a carcinogenic metabolite produced by pathogenic gut bacteria associated with colorectal cancer (CRC). The project, which commenced September 10, 2025, and extends through August 31, 2029, focuses on engineering...
- This $1,355,273 Project Grant was awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) to the Regents of the University of Michigan. The grant funds the development of two complementary approaches to inhibit the production of the bacterial metabolite colibactin, which has been linked to colorectal cancer and microbiome dysbiosis. The first approach involves enzymatic inactivation of colibactin through...
- Federal Cooperative Agreement Award Summary The National Cancer Institute awarded $323,226 to the University of Michigan's Office of Research and Sponsored Projects under the Cancer Cause and Prevention Research program (CFDA 93.393) effective August 1, 2025, through July 31, 2028. This Cooperative Agreement funds research focused on developing natural products targeting interleukin-8 (IL-8) signaling to intercept the progression of Barrett's esophagus to esophageal adenocarcinoma (EAC), a...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $669,278 to the University of Michigan's Office of Research and Sponsored Projects, effective June 1, 2026 through May 31, 2031, under the Cancer Treatment Research program (CFDA 93.395). This Multi-Principal Investigator (MPI) R01 application, aligned with PAR-25-107 (Advancing Microbial-Based Cancer Therapy), supports the development of engineered nonpathogenic tumor-tropic E. coli bacteria...
- Federal Cooperative Agreement Summary The National Cancer Institute (NCI) awarded a $1.45 million Cooperative Agreement to The Trustees of Columbia University in the City of New York (Health Sciences Division) under the Cancer Biology Research program (CFDA 93.396) on August 11, 2025, with completion targeted for May 31, 2027. The award funds research and development of engineered probiotic bacteria, specifically E. coli Nissle 1917 (ECN), designed to identify precancerous colorectal lesions and...
- Federal Grant Award Summary The National Cancer Institute awarded the University of Michigan $682,272 under the Cancer Cause and Prevention Research program (CFDA 93.393) on September 1, 2025, for a two-year project (completion date August 31, 2027) to assess the feasibility and acceptability of a multifaceted electronic health record (EHR)-integrated mobile health intervention designed to reduce post-operative readmissions following radical cystectomy. The intervention consists of an...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $293,430 to the University of Michigan's Office of Research and Sponsored Projects on June 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support a five-year research initiative examining regional cancer care delivery optimization. The project, led by a colorectal surgeon and health services researcher, will leverage Michigan's Collaborative Quality Initiatives (CQIs) as a learning laboratory to...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Broad Institute of MIT and Harvard a $795,544 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) effective August 1, 2025, with completion targeted for July 31, 2027. This award funds the development of computational methods for profiling the cancer virome and microbial strain genetics from shotgun metagenomes and metatranscriptomes. The deliverables include novel algorithms that integrate...
- Federal Grant Award Summary The University of Michigan, through its Office of Research and Sponsored Projects, received a $544,868 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), effective June 1, 2026, through May 31, 2031. The award supports research investigating SLC13A3 and its role in tumor resistance to immunotherapy, with a focus on understanding how the itaconate-SLC13A3 metabolic axis suppresses major histocompatibility...
- Federal Cooperative Agreement Summary The University of Michigan received a $210,600 Cooperative Agreement from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394), effective September 1, 2025, through August 31, 2027. This award supports the analytical and clinical validation of an H3K27M circulating tumor DNA (ctDNA) assay designed to improve disease monitoring and early detection of progression in diffuse midline glioma (DMG) patients. The...